natgillin/translations-raw huggingface dataset:
International non-proprietary name (INN): lacosamide 
Mednarodno nelastniško ime (INN): lakosamid
This withdrawal has no consequences on Vimpat, for which the balance of benefits and risks remains unchanged. 
Umik nima nobenih posledic za zdravilo Vimpat, za katerega razmerje med koristmi in tveganji ostaja nespremenjeno.
The main measure of effectiveness was the change in pain levels between the start of the study and the last four weeks on the stable dose. 
Glavno merilo učinkovitosti je bila sprememba v ravneh bolečine ob začetku študije ter v zadnjih štirih tednih ob prejemanju stabilnega odmerka.
The effectiveness of three doses of Lacosamide Pain UCB Pharma (200, 400 and 600 mg per day) was compared with that of placebo (a dummy treatment) in a total of 1,724 patients in four main studies. 
Učinkovitost treh odmerkov zdravila Lacosamide Pain UCB Pharma (200, 400 in 600 mg na dan) so primerjali s placebom (zdravilom brez zdravilne učinkovine) pri skupaj 1 724 bolnikih v štirih glavnih študijah.
The exact way in which lacosamide works is still unclear, but it seems to reduce the activity of sodium channels (pores on the surface of nerve cells) that allow electrical impulses to be transmitted between nerve cells. 
Natančen način delovanja lakosamida še vedno ni jasen, vendar se zdi, da zmanjša dejavnost natrijevih kanalov (por na površini živčnih celic), ki omogočajo, da se električni impulzi prenašajo med živčnimi celicami.
Ref. EMEA/522632/2008 
EMEA/605943/2008 Error!
Lacosamide has been authorised in the European Union (EU) as an anti-epileptic medicine under the trade name Vimpat since August 2008. 
Lakosamid je v Evropski uniji odobren kot antiepileptično zdravilo pod lastniškim imenom Vimpat od avgusta 2008.
Together, these actions are expected to prevent abnormal electrical activity in nerve cells, reducing pain due to nerve damage. 
Pričakuje se, da te dejavnosti skupaj preprečujejo električno dejavnost v živčnih celicah in tako zmanjšujejo bolečino zaradi poškodbe živcev.
Pain was measured by the patients on an 11-point scale. 
Bolniki so bolečino merili s pomočjo 11-stopenjske lestvice.
In all four studies, the dose of Lacosamide Pain UCB Pharma was increased gradually over a few weeks before being maintained at a stable dose for 12 weeks. 
V vseh štirih študijah so odmerek zdravila Lacosamide Pain UCB Pharma postopoma povečevali v obdobju nekaj tednov, nato pa 12 tednov vzdrževali na stabilni ravni.
The application was at day 181 when the company withdrew. 
Družba je vlogo umaknila na 181. dan postopka.
The effects of Lacosamide Pain UCB Pharma were first tested in experimental models before being studied in humans. 
Učinki zdravila Lacosamide Pain UCB Pharma so bili najprej preskušeni na poskusnih modelih, nato pa so jih raziskali pri ljudeh.
What is happening with Vimpat used for the treatment of epilepsy? 
Kaj to pomeni za nadaljnjo uporabo zdravila Vimpat, ki se uporablja za zdravljenje epilepsije?
Lacosamide Pain UCB Pharma was expected to be used in adults to treat pain due to diabetic peripheral neuropathy (damage to the nerves in the extremities that can occur in patients with diabetes). 
Zdravilo Lacosamide Pain UCB Pharma naj bi se uporabljalo pri odraslih za zdravljenje bolečine, ki jo povzroča diabetična periferna nevropatija (poškodbe živcev v okončinah, ki se lahko pojavijo pri bolnikih z diabetesom).
Lacosamide is also thought to be involved in the development of nerve cells that have been damaged. 
Zdi se, da lakosamid sodeluje tudi pri razvoju živčnih celic, ki so bile poškodovane.
On 25 September 2008, UCB Pharma S.A. officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Lacosamide Pain UCB Pharma, for the treatment of diabetic neuropathic pain in adults. 
Družba UCB Pharma S.A. je dne 25. septembra 2008 uradno obvestila Odbor za zdravila za uporabo v humani medicini (CHMP), da želi umakniti vlogo za dovoljenje za promet z zdravilom Lacosamide Pain UCB Pharma, namenjenim zdravljenju boleče diabetične nevropatije pri odraslih.
Based on the review of the data and the company's response to the CHMP list of questions, at the time of the withdrawal, the CHMP had some concerns and was of the provisional opinion that Lacosamide Pain UCB Pharma could not have been approved for the treatment of diabetic neuropathic pain in adults. 
Na podlagi pregleda podatkov in odgovorov družbe na seznam vprašanj, ki jih je zastavil CHMP v času umika vloge, je imel Odbor zadržke in je začasno menil, da zdravila Lacosamide Pain UCB Pharma ni mogoče odobriti za zdravljenje boleče diabetične nevropatije pri odraslih.
Questions and answers on the withdrawal of the marketing application for Lacosamide Pain UCB Pharma 
Vprašanja in odgovori v zvezi z umikom vloge za dovoljenje za promet z zdravilom Lacosamide Pain UCB Pharma
The medicine can also cause side effects affecting the heart and central nervous system (such as dizziness), which are of concern in patients with diabetes. 
Zdravilo lahko povzroči tudi neželene učinke, ki vplivajo na srce in osrednji živčni sistem (kot je omotica).
What are the consequences of the withdrawal for patients undergoing clinical trials or compassionate use programmes with Lacosamide Pain UCB Pharma? 
Kakšne so posledice umika za bolnike, ki sodelujejo v kliničnih preskušanjih ali programih sočutne uporabe zdravila Lacosamide Pain UCB Pharma?
The CHMP was concerned that the studies had not shown a meaningful benefit of Lacosamide Pain UCB Pharma. 
CHMP je izrazil pomislek, da študije niso dokazale bistvene koristi zdravila Lacosamide Pain UCB Pharma.
Therefore, at the time of the withdrawal, the CHMP's view was that a benefit of Lacosamide Pain UCB Pharma had not been sufficiently demonstrated and any benefits did not outweigh the identified risks. 
CHMP je zato v času umika menil, da koristi zdravila Lacosamide Pain UCB Pharma niso bile zadostno dokazane in da ne odtehtajo znanih tveganj.
The company informed the CHMP that there are no consequences for patients currently included in clinical trials or compassionate use programmes with Lacosamide Pain UCB Pharma. 
Družba je obvestila CHMP, da za bolnike, ki trenutno sodelujejo v kliničnih preskušanjih ali programih sočutne uporabe z zdravilom Lacosamide Pain UCB Pharma, ni nobenih posledic.
What is Lacosamide Pain UCB Pharma? 
Kaj je zdravilo Lacosamide Pain UCB Pharma?
Lacosamide Pain UCB Pharma contains the active substance lacosamide. 
Zdravilo Lacosamide Pain UCB Pharma vsebuje zdravilno učinkovino lakosamid.
How is Lacosamide Pain UCB Pharma expected to work? 
Kako naj bi zdravilo Lacosamide Pain UCB Pharma delovalo?
What was Lacosamide Pain UCB Pharma expected to be used for? 
Za kaj naj bi se zdravilo Lacosamide Pain UCB Pharma uporabljalo?
Medicinal product no longer authorised 
Številka (EU) dovoljenja za promet
Subcutaneous use pre-filled syringe 1.0 ml (150 mg/ml) 3 (3 x 1) pre-filled syringes (multipack) 
1,0 ml (150 mg/ml) 3 (3 x 1) napolnjene injekcijske brizge (večkratno pakiranje)
Subcutaneous use pre-filled pen 1.0 ml (150 mg/ml) 3 (3 x 1) pre-filled pens (multipack) 
1,0 ml (150 mg/ml) 3 (3 x 1) napolnjeni injekcijski peresniki (večkratno pakiranje)
Subcutaneous use pre-filled syringe 1.0 ml (150 mg/ml) 1 pre-filled syringe 
1,0 ml (150 mg/ml) 1 napolnjena injekcijska brizga
Subcutaneous use pre-filled pen 1.0 ml (150 mg/ml) 1 pre-filled pen 
1,0 ml (150 mg/ml) 1 napolnjen injekcijski peresnik
Treatment should not be stopped abruptly. 
Zdravljenje se ne sme prekiniti nenadoma.
The European Commission granted a marketing authorisation valid throughout the European Union for INOmax on 1 August 2001. 
Evropska komisija je dovoljenje za promet z zdravilom INOmax, veljavno po vsej Evropski uniji, odobrila dne 1. avgusta 2001.
In children and adults undergoing heart surgery, treatment usually lasts for 24 to 48 hours. 
Pri otrocih in odraslih pred operacijo srca zdravljenje običajno traja od 24 do 48 ur.
INOmax nitric oxide 
INOmax dušikov oksid
This should then be reduced to 5 ppm, provided the blood in the arteries contains enough oxygen. 
To je treba kasneje zmanjšati na 5 ppm, če kri v arterijah vsebuje dovolj kisika.
The full EPAR for INOmax can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo INOmax je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
This is a summary of the European public assessment report (EPAR) for INOmax. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo INOmax.
It also helps to decrease inflammation in the lungs. 
Pomaga tudi pri zmanjševanju vnetij v pljučih.
The maximum starting dose of INOmax is 20 ppm for children up to 18 years of age, and 40 ppm for adults. 
Največji začetni odmerek zdravila INOmax je 20 ppm za otroke do 18. leta starosti in 40 ppm za odrasle.
For more information about treatment with INOmax, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.. 
Za več informacij o zdravljenju z zdravilom INOmax preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
What measures are being taken to ensure the safe use of INOmax? 
Kateri ukrepi se izvajajo za zagotovitev varne uporabe zdravila INOmax?
• newborn babies (born after 34 weeks of gestation) with breathing problems associated with pulmonary hypertension (high blood pressure in the lungs). 
• novorojenčkih (rojeni po 34. tednu nosečnosti) s težavami pri dihanju zaradi pljučne hipertenzije (visok krvni tlak v pljučih).
The company must put in place an educational programme to ensure that doctors who are going to use INOmax for the treatment of patients undergoing heart surgery are aware of the risks and the precautions necessary when using the medicine. 
Družba mora pripraviti izobraževalni program za zdravnike, ki bodo zdravilo INOmax uporabljali pri zdravljenju bolnikov pred operacijo srca, ter tako zagotoviti njihovo poznavanje tveganj in previdnostnih ukrepov pri uporabi zdravila.
The main measure of effectiveness was the proportion of neonates who died or needed ECMO over the first 120 days in hospital. 
Glavno merilo učinkovitosti je bil delež novorojenčkov, ki so umrli ali so potrebovali zunajtelesno membransko oksigenacijo v prvih 120 dneh v bolnišnici.
INOmax treatment should be supervised by a doctor who has experience in intensive care or neonatal intensive care if the patient is a newborn baby. 
Zdravljenje z zdravilom INOmax mora nadzorovati zdravnik, ki ima izkušnje z intenzivno nego ali intenzivno nego novorojenčkov, če je bolnik novorojenček.
The Committee for Medicinal Products for Human Use (CHMP) decided that INOmax's benefits are greater than its risks and recommended that it be given marketing authorisation. 
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila INOmax večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
• patients of all ages who are undergoing or have undergone heart surgery and develop pulmonary hypertension. 
• bolnikih vseh starosti, pri katerih bo ali je bil opravljen kirurški poseg na srcu in pri katerih se je pojavila pljučna hipertenzija.
What benefit has INOmax shown during the studies? 
Kakšne koristi je zdravilo INOmax izkazalo med študijami?
It must not be used in babies who have right-to-left or significant left-to-right shunting of blood (abnormal circulation of blood in the heart). 
Prav tako se ne sme uporabljati pri dojenčkih, ki imajo obvod krvi z desne na levo ali izrazit obvod krvi z leve na desno (nenormalen obtok krvi v srcu).
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for INOmax. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo INOmax, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
Other information about INOmax 
Druge informacije o zdravilu INOmax:
INOmax is a gas for inhalation that contains the active substance nitric oxide diluted in nitrogen gas at 400 or 800 parts per million (ppm). 
Zdravilo INOmax je plin za inhaliranje, ki vsebuje zdravilno učinkovino dušikov oksid, razredčen v plinu dušiku v koncentraciji 400 ali 800 delcev na milijon (ppm).
INOmax is used in combination with artificial ventilation and other medicines to help improve blood oxygen levels in the following groups of patients: 
Zdravilo INOmax se uporablja v kombinaciji z umetnim predihavanjem in drugimi zdravili za izboljšanje koncentracije kisika v krvi pri naslednjih skupinah bolnikov:
The most common side effect with INOmax (seen in more than 1 patient in 10) are thrombocytopenia (low blood platelet counts), hypokalaemia (low blood potassium levels), hypotension (low blood pressure), atelectasis (collapse of the whole, or part of a, lung), and hyperbilirubinaemia (high blood levels of bilirubin). 
Najpogostejši neželeni učinki zdravila INOmax (opaženi pri več kot 1 bolniku izmed 10) je trombocitopenija (nizka koncentracija trombocitov v krvi), hipokaliemija (nizka raven kalija v krvi), hipotenzija (nizek krvni tlak), atelektaza (kolaps celih pljuč ali dela pljuč) in hiperbilirubinemija (visoka koncentracija bilirubina v krvi).
INOmax should not be used in babies who may be hypersensitive (allergic) to nitric oxide or the other ingredient (nitrogen). 
Zdravilo INOmax se ne sme uporabljati pri dojenčkih, ki utegnejo biti preobčutljivi za (alergični na) dušikov oksid ali drugo sestavino zdravila (dušik).
In the second main study, 30 (31%) of the neonates receiving INOmax needed ECMO, compared with 51 (57%) of the 89 receiving placebo. 
V drugi glavni študiji je zunajtelesno membransko oksigenacijo potrebovalo 30 (31 %) novorojenčkov, ki so prejemali zdravilo INOmax, v primerjavi z 51 (57 %) izmed 89 novorojenčkov, ki so prejemali placebo.
INOmax is given after being diluted in an oxygen/air mixture supplied to the patient through the ventilator. 
Zdravilo INOmax se daje razredčeno v mešanici kisika/zraka, ki se bolniku dovaja skozi ventilator.
In the first main study, 52 (46%) of the 114 neonates receiving INOmax died or needed ECMO, compared with 77 (64%) of the 121 receiving placebo. 
V prvi glavni študiji je umrlo ali potrebovalo zunajtelesno membransko oksigenacijo 52 (46 %) izmed 114 novorojenčkov, ki so prejemali zdravilo INOmax, v primerjavi s 77 (64 %) izmed 121 novorojenčkov, ki so prejemali placebo.
INOmax has also been studied in 421 neonates from 34 weeks gestation with pulmonary hypertension in two main studies. 
Zdravilo INOmax so proučevali tudi v dveh glavnih študijah s 421 novorojenčki s pljučno hipertenzijo, rojenimi po vsaj 34 tednih nosečnosti.
In the published literature, INOmax treatment was shown to reduce the blood pressure in the lungs and improve heart function when used during or after heart surgery. 
V objavljeni literaturi se je izkazalo, da je zdravljenje z zdravilom INOmax znižalo krvni tlak v pljučih in izboljšalo delovanje srca, kadar je bilo uporabljeno med operacijo srca ali po njej.
In these patients INOmax is used to help improve heart function and reduce blood pressure in the lungs. 
Pri teh bolnikih se zdravilo INOmax uporablja za izboljšanje delovanje srca in znižanje krvnega tlaka v pljučih.
INOmax should only be used in units where staff have been trained in the use of a nitric oxide delivery system. 
Zdravilo INOmax se sme uporabljati samo na oddelkih, katerih osebje je usposobljeno za uporabo sistema za dovajanje dušikovega oksida.
What is the risk associated with INOmax? 
Kakšna tveganja so povezana z zdravilom INOmax?
The marketing authorisation holder is Linde Healthcare AB. 
Imetnik dovoljenja za promet z zdravilom je družba Linde Healthcare AB.
This was mainly due to a reduction in the need for ECMO, rather than a reduction in death rates. 
Razlika je bila pretežno pogojena z zmanjšanjem potrebe po zunajtelesni membranski oksigenaciji in ne zmanjšanjem smrtnosti.
Because nitric oxide is a well-known chemical, the company used data from the published literature to support INOmax's use in newborn babies with pulmonary hypertension, and in adults and children undergoing heart surgery. 
Ker je dušikov oksid dobro znana kemična snov, je družba v podporo uporabi zdravila INOmax pri novorojenčkih s pljučno hipertenzijo ter pri odraslih in otrocih pred operacijo srca uporabila podatke iz objavljene literature.
For the full list of all side effects reported with INOmax, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila INOmax, glejte navodilo za uporabo.
In newborn babies with breathing problems, treatment can be continued at this dose until there is improvement in oxygen levels, for a maximum of four days. 
Zdravljenje s tem odmerkom se lahko pri novorojenčkih s težavami pri dihanju nadaljuje, dokler se koncentracija kisika ne izboljša, vendar ne sme trajati več kot štiri dni.
In the second study, 186 neonates with respiratory failure received either INOmax or placebo. 
V drugi študiji je 186 novorojenčkov z respiratorno odpovedjo prejemalo bodisi zdravilo INOmax ali pa placebo.
When inhaled, it causes the vessels in the lungs to dilate (widen); this allows blood to flow more easily in the lungs to supply oxygen to the rest of the body and remove carbon dioxide, reducing pulmonary hypertension. 
Pri vdihavanju povzroči širjenje žil v pljučih, kar omogoča lažje dovajanje krvi v pljuča za oskrbo preostalega telesa s kisikom in odstranjevanje ogljikovega dioksida, s čimer se zmanjšuje pljučna hipertenzija.
INOmax is used in these babies to improve oxygen supply levels and to reduce the need for extracorporeal membrane oxygenation (ECMO, a technique to oxygenate the blood outside the body using a device similar to a heart-lung machine). 
Zdravilo INOmax se pri teh dojenčkih uporablja za izboljšanje koncentracije kisika in zmanjšanje potrebe po zunajtelesni membranski oksigenaciji (ECMO, tehnika za oksigenizacijo krvi zunaj telesa z uporabo naprave, podobne aparatu srce-pljuča);
Why has INOmax been approved? 
Zakaj je bilo zdravilo INOmax odobreno?
In the two main studies in newborn babies with breathing problems, INOmax was more effective than placebo at reducing the need of ECMO. 
V dveh glavnih študijah pri novorojenčkih s težavami pri dihanju je bilo zdravilo INOmax učinkovitejše od placeba pri zmanjševanju potrebe po zunajtelesni membranski oksigenaciji.
The active substance in INOmax, nitric oxide, is a naturally-occurring chemical in the body, which causes the muscles in the lining of the blood vessels to relax. 
Zdravilna učinkovina v zdravilu INOmax, dušikov oksid, je kemična snov, ki je v telesu naravno prisotna in povzroča sproščanje mišic v steni krvnih žil.
The main measure of effectiveness was the proportion of neonates who needed ECMO. 
Glavno merilo učinkovitosti je bil delež novorojenčkov, ki so potrebovali zunajtelesno membransko oksigenacijo.
In the first study, 235 neonates with respiratory failure received either INOmax or placebo (a dummy treatment). 
V prvi študiji je 235 novorojenčkov z respiratorno odpovedjo prejemalo bodisi zdravilo INOmax ali pa placebo (zdravilo brez zdravilne učinkovine).
INOmax is used in patients who are undergoing artificial ventilation, once the ventilation is optimised. 
Zdravilo INOmax se uporablja pri bolnikih, pri katerih se izvaja umetno predihavanje, po optimizaciji predihavanja.
How has INOmax been studied? 
Kako je bilo zdravilo INOmax raziskano?
What is INOmax used for? 
Za kaj se zdravilo INOmax uporablja?
How is INOmax used? 
Kako se zdravilo INOmax uporablja?
How does INOmax work? 
Kako zdravilo INOmax deluje?
What is INOmax? 
Kaj je zdravilo INOmax?
and 5.1). 
4.5 in 5.1).
(see section 5.3). 
(glejte poglavje 5.1).
This medicinal product should not be given to children under 18 years of age because the safety and efficacy have not yet been fully established. 
Otroci in mladostniki Tega zdravila ne smete dajati otrokom, mlajšim od 18 let, ker varnost in učinkovitost še nista bili popolnoma ugotovljeni.
You may need to have blood checks if you take: 
Morda bodo potrebe krvne preiskave, če jemljete:
If you suffer from heart problems 
• če imate težave s srcem
Swensweg 5, Postbus 552 2003 RN Haarlem The Netherlands 
Swensweg 5, Postbus 552 2003 RN Haarlem Nizozemska
Currently available data are described in sections 4.8, 5.1, and 5.2 but no recommendation on a posology can be made. 
Trenutno razpoložljivi podatki so opisani v poglavju 4.8, 5.1 in 5.2 vendar priporočil o odmerjanju ni mogoče dati.
Date of first authorisation: 30 October 2009 Date of latest renewal: 18 July 2014 
Datum zadnjega podaljšanja: 18. julij 2014
Plasma protein binding is approximately 96 %, with negligible binding to cellular blood components. 
Vezava na plazemske beljakovine je približno 96 %, z zanemarljivo vezavo na krvne celice.
You can take Irbesartan Teva with or without food. 
Zdravilo Irbesartan Teva lahko jemljete s hrano ali brez nje.
• Second and third trimesters of pregnancy (see section 4.4 and 4.6). 
• Drugo in tretje trimesečje nosečnosti (glejte poglavji 4.4 in 4.6).
After oral administration, irbesartan is well absorbed: studies of absolute bioavailability gave values of approximately 60-80 %. 
Irbesartan se po peroralni uporabi dobro absorbira: študije absolutne biološke razpoložljivosti so dale vrednosti približno 60-80 %.
The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch. 
V natisnjem navodilu za uporabo zdravila mora biti navedeno ime in naslov izdelovalca, odgovornega za sproščanje zadevne serije.
Swallow the tablets with a sufficient amount of fluid (e.g. one glass of water). 
Tablete morate pogoltniniti z zadostno količino tekočine (npr. z enim kozarcem vode).
The total body and renal clearance are 157-176 and 3-3.5 ml/min, respectively. 
Celokupni telesni in ledvični očistek je 157-176 oziroma 3-3,5 ml/min.
The patient should be closely monitored, and the treatment should be symptomatic and supportive. 
zdravljenje pa mora biti simptomatsko in podporno.
The frequency of adverse reactions listed below is defined using the following convention: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to 
Pogostnost spodaj naštetih neželenih učinkov je opredeljena po naslednjem dogovoru: zelo pogosti (≥ 1/10); pogosti (≥ 1/100 do < 1/10); občasni (≥ 1/1.000 do < 1/100); redki (≥ 1/10.000 do < 1/1.000); zelo redki (< 1/10.000).
The major circulating metabolite is irbesartan glucuronide (approximately 6 %). 
Glavni metabolit v obtoku je irbesartan glukuronid (približno 6 %).
The safety and efficacy of Irbesartan Teva in children aged 0 to 18 has not been established. 
Varnost in učinkovitost zdravila Irbesartan Teva pri otrocih, starih od 0 do 18 let, nista bili dokazani.
At 24 hours the reduction of blood pressure was 60-70 % of the corresponding peak diastolic and systolic responses at the recommended doses. 
Po 24 urah je bilo zmanjšanje krvnega tlaka 60-70 % ustreznega največjega diastoličnega in sistoličnega odziva na priporočeni odmerek.
The predefined blood pressure goal was ≤ 135/85 mm Hg. 
Ciljni krvni tlak je bil ≤ 135/85 mmHg.
See also information under the heading “Do not take Irbesartan Teva”. 
Glejte tudi informacije pod naslovom “Ne jemljite zdravila Irbesartan Teva”.
31-546 Kraków 
Mogilska 80 31-546 Kraków
Irbesartan AUC and Cmax values were also somewhat greater in elderly subjects (≥ 65 years) than those of young subjects (18-40 years). 
Vrednosti AUC in Cmax irbesartana so bile pri starejših osebah (≥ 65 let) nekoliko večje kot pri mlajših (18-40 let).